These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 2449564)

  • 1. The effectiveness of inotropic agents in isolated cardiac preparations from the human heart.
    Erdmann E
    Klin Wochenschr; 1988 Jan; 66(1):1-6. PubMed ID: 2449564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduction of beta-adrenoceptor density and evaluation of positive inotropic responses in isolated, diseased human myocardium.
    Böhm M; Beuckelmann D; Brown L; Feiler G; Lorenz B; Näbauer M; Kemkes B; Erdmann E
    Eur Heart J; 1988 Aug; 9(8):844-52. PubMed ID: 2460351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calcium sensitization as new principle of inotropic therapy in end-stage heart failure?
    Zimmermann N; Boknik P; Gams E; Herzig JW; Neumann J; Scholz H
    Eur J Cardiothorac Surg; 1998 Jul; 14(1):70-5. PubMed ID: 9726618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanism underlying the reduced positive inotropic effects of the phosphodiesterase III inhibitors pimobendan, adibendan and saterinone in failing as compared to nonfailing human cardiac muscle preparations.
    von der Leyen H; Mende U; Meyer W; Neumann J; Nose M; Schmitz W; Scholz H; Starbatty J; Stein B; Wenzlaff H
    Naunyn Schmiedebergs Arch Pharmacol; 1991 Jul; 344(1):90-100. PubMed ID: 1723153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Positive inotropic effects in isolated ventricular myocardium from non-failing and terminally failing human hearts.
    Näbauer M; Böhm M; Brown L; Diet F; Eichhorn M; Kemkes B; Pieske B; Erdmann E
    Eur J Clin Invest; 1988 Dec; 18(6):600-6. PubMed ID: 2465159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Screening of positive inotropic agents in isolated cardiac preparations from different sources.
    Böhm M; Diet F; Pieske B; Erdmann E
    J Pharmacol Methods; 1989 Mar; 21(1):33-44. PubMed ID: 2704246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of inotropic interventions on the force-frequency relation in the human heart.
    Bavendiek U; Brixius K; Münch G; Zobel C; Müller-Ehmsen J; Schwinger RH
    Basic Res Cardiol; 1998; 93 Suppl 1():76-85. PubMed ID: 9833134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of cantharidin on force of contraction and phosphatase activity in nonfailing and failing human hearts.
    Linck B; Boknik P; Knapp J; Müller FU; Neumann J; Schmitz W; Vahlensieck U
    Br J Pharmacol; 1996 Oct; 119(3):545-50. PubMed ID: 8894176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [New cardiotonic/inodilator agents: energetic aspects].
    Hasenfuss G
    Z Kardiol; 1992; 81 Suppl 4():57-63. PubMed ID: 1290307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin-like growth factor-1 exerts Ca2+-dependent positive inotropic effects in failing human myocardium.
    von Lewinski D; Voss K; Hülsmann S; Kögler H; Pieske B
    Circ Res; 2003 Feb; 92(2):169-76. PubMed ID: 12574144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological and biochemical effects of the cardiotonic agent Org10325 in isolated cardiac and vascular tissue preparations.
    Shahid M; Martorana MG; Cottney JE; Marshall RJ
    Br J Pharmacol; 1990 Aug; 100(4):735-42. PubMed ID: 2169938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of forskolin on the force-frequency behavior in nonfailing and end-stage failing human myocardium.
    Pieske B; Trost S; Schütt K; Minami K; Just H; Hasenfuss G
    Basic Res Cardiol; 1998; 93 Suppl 1():66-75. PubMed ID: 9833133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Positive inotropic effects of the novel Na+-channel modulator BDF 9198 in human nonfailing and failing myocardium.
    Müller-Ehmsen J; Brixius K; Schwinger RH
    J Cardiovasc Pharmacol; 1998 May; 31(5):684-9. PubMed ID: 9593067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deficient production of cyclic AMP: pharmacologic evidence of an important cause of contractile dysfunction in patients with end-stage heart failure.
    Feldman MD; Copelas L; Gwathmey JK; Phillips P; Warren SE; Schoen FJ; Grossman W; Morgan JP
    Circulation; 1987 Feb; 75(2):331-9. PubMed ID: 2433073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increase in force of contraction by activation of the Na+/Ca(2+)-exchanger in human myocardium.
    Müller-Ehmsen J; Frank K; Brixius K; Schwinger RH
    Br J Clin Pharmacol; 1997 Apr; 43(4):399-405. PubMed ID: 9146852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of positive inotropes on the failing human myocardium.
    Erdmann E
    Cardiology; 1997; 88 Suppl 2():7-11. PubMed ID: 9142430
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence for a sustained effectiveness of sodium-channel activators in failing human myocardium.
    Schwinger RH; Böhm M; Mittmann C; La Rosée K; Erdmann E
    J Mol Cell Cardiol; 1991 Apr; 23(4):461-71. PubMed ID: 1658340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacology and inotropic potential of forskolin in the human heart.
    Bristow MR; Ginsburg R; Strosberg A; Montgomery W; Minobe W
    J Clin Invest; 1984 Jul; 74(1):212-23. PubMed ID: 6330174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effect of nitroglycerin on the contractility of the myocardium under various supplies of oxygen].
    Bezus'ko AG; Shavaran SS; Bratus' VV
    Fiziol Zh SSSR Im I M Sechenova; 1988 Mar; 74(3):390-5. PubMed ID: 3133252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adenylyl cyclase-mediated effects contribute to increased Isoprenaline-induced cardiac contractility in TRPM4-deficient mice.
    Uhl S; Mathar I; Vennekens R; Freichel M
    J Mol Cell Cardiol; 2014 Sep; 74():307-17. PubMed ID: 24972051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.